Abstract
NADPH oxidases (NOX), catalyzing the reduction of molecular oxygen to form the superoxide radical anion (•O2 -) and hydrogen peroxide (H2O2), are involved in several pathological conditions, such as stroke, diabetes, atherosclerosis, but also in chronic neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, or multiple sclerosis. GKT136901 is a novel NOX-1/4 inhibitor with potential application in the areas of diabetic nephropathy, stroke, or neurodegeneration. In the present study, we investigated additional pharmacological activities of the compound with respect to direct free radical scavenging. GKT136901 did not interact with nitric oxide (•NO), •O2 -, or hydroxyl radicals (•OH), but it acted as selective scavenger of peroxynitrite (PON) already in the submicromolar concentration range. Alpha synuclein (ASYN) is a protein involved in the pathogenesis of Parkinson’s disease and a known target for PON-dependent tyrosine nitration. Submicromolar concentrations of GKT136901 prevented tyrosine nitration and di-tyrosine-dependent dimer formation of ASYN by PON as indicated by Western blot and mass spectrometric analysis. GKT136901 itself was degraded when exposed to PON. In a human neuronal cell model, GKT136901 prevented both the depletion of reduced intracellular glutathione, and the degeneration of neurites when present during PON treatment of the cells. When GKT136901 was applied after PON treatment, no protective effect was observed, thus excluding an impact of GKT136901 on cellular death/survival pathways. In summary, selective scavenging of PON is an additional pharmacological property of the NOX-1/4 inhibitor GKT136901, and this may add to the efficiency of the drug in several disease models.
Keywords: Alpha synuclein, GKT136901, LUHMES, NADPH oxidase, NOX, peroxynitrite.
Current Medicinal Chemistry
Title:The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite
Volume: 21 Issue: 3
Author(s): S. Schildknecht, A. Weber, H. R. Gerding, R. Pape, M. Robotta, M. Drescher, A. Marquardt, A. Daiber, B. Ferger and M. Leist
Affiliation:
Keywords: Alpha synuclein, GKT136901, LUHMES, NADPH oxidase, NOX, peroxynitrite.
Abstract: NADPH oxidases (NOX), catalyzing the reduction of molecular oxygen to form the superoxide radical anion (•O2 -) and hydrogen peroxide (H2O2), are involved in several pathological conditions, such as stroke, diabetes, atherosclerosis, but also in chronic neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, or multiple sclerosis. GKT136901 is a novel NOX-1/4 inhibitor with potential application in the areas of diabetic nephropathy, stroke, or neurodegeneration. In the present study, we investigated additional pharmacological activities of the compound with respect to direct free radical scavenging. GKT136901 did not interact with nitric oxide (•NO), •O2 -, or hydroxyl radicals (•OH), but it acted as selective scavenger of peroxynitrite (PON) already in the submicromolar concentration range. Alpha synuclein (ASYN) is a protein involved in the pathogenesis of Parkinson’s disease and a known target for PON-dependent tyrosine nitration. Submicromolar concentrations of GKT136901 prevented tyrosine nitration and di-tyrosine-dependent dimer formation of ASYN by PON as indicated by Western blot and mass spectrometric analysis. GKT136901 itself was degraded when exposed to PON. In a human neuronal cell model, GKT136901 prevented both the depletion of reduced intracellular glutathione, and the degeneration of neurites when present during PON treatment of the cells. When GKT136901 was applied after PON treatment, no protective effect was observed, thus excluding an impact of GKT136901 on cellular death/survival pathways. In summary, selective scavenging of PON is an additional pharmacological property of the NOX-1/4 inhibitor GKT136901, and this may add to the efficiency of the drug in several disease models.
Export Options
About this article
Cite this article as:
Schildknecht S., Weber A., Gerding R. H., Pape R., Robotta M., Drescher M., Marquardt A., Daiber A., Ferger B. and Leist M., The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite, Current Medicinal Chemistry 2014; 21 (3) . https://dx.doi.org/10.2174/09298673113209990179
DOI https://dx.doi.org/10.2174/09298673113209990179 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Synthetic Methods for the Preparation of Triazepandiones and Review of their Applications
Current Organic Chemistry Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Cell Therapies for IBD: What Works?
Current Drug Targets Formulation and In Vitro Evaluation of Gelatin Nanospheres for the Oral Delivery of Selegiline
Current Nanoscience Editorial
Current Molecular Medicine Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease
Current Alzheimer Research Commentary: Histaminergic Drugs Could be Novel Targets for Neuroprotection in CNS Disorders
CNS & Neurological Disorders - Drug Targets Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Monitoring the Inflammatory Process by Surface Enhanced Nanoimaging Microscopy
Current Neurovascular Research The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry